Astellas gains an option on Audax’s IL-12 antibody-cytokine fusion DAX-044, while EVERSANA acquires London-based health economics firm Estima Scientific.
|Articles|February 1, 2019
- Pharmaceutical Executive-02-01-2019
- Volume 39
- Issue 2
Pharmaceutical Executive, February 2019 Issue (PDF)
Click the title above to open the Pharmaceutical Executive February 2019 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 7 years ago
Q&A: Regulatory Reform in Chinaover 7 years ago
China: A Change in Attitudeover 7 years ago
New Roads to Chinaover 7 years ago
Closing the Pharma and Digital Health Divideover 7 years ago
A Leading Man’s Next Actover 7 years ago
Two Steps Forwardover 7 years ago
Let the Drug Pricing Games Beginover 7 years ago
Mixed Outlook for China Life Sciencesover 7 years ago
CFIUS Reform’s Impact on Biopharmaover 7 years ago
Op-Ed: Opening the Golden DoorAdvertisement
Related to this article
Shionogi’s Dr. Draica on why preventative antivirals matter — and how its HIV and flu prevention heritage shaped XOCOVA’s post-exposure focus.
The infrastructure decisions companies make today could determine how quickly they capitalize on new computational capabilities
Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.
The top barrier to AI adoption among pharma commercial leaders is compliance uncertainty, and the fix may be governance that evaluates one use case at a time.
Teva acquires BioXcel’s BXCL501, under FDA review for at-home agitation use; Rumi Therapeutics gains an option on Enthorin’s Fragile X PDE2 inhibitor.
Brox.AI’s Hamish Brocklebank on the three approaches to digital twins in pharma — and why only one-to-one clones of real individuals deliver true accuracy.
Shionogi’s Dr. Draica on how XOCOVA blocks viral replication between exposure and symptoms — and why it works even with prior immunity.
Advertisement
Advertisement
Trending on PharmExec
1
The Next Biopharma Revolution: Quantum Computing
2
Roundup: Astellas Licenses IL-12 Fusion Protein From Audax in Deal Worth Up to $1.34 Billion, EVERSANA Acquires Health Economics Firm Estima Scientific
3
How Medications like XOCOVA Prevent Illness After Exposure to COVID-19
4
Roundup: Teva Acquires BXCL501 for $57.5 Million Upfront, Rumi Therapeutics Enters Option Agreement for Fragile X PDE2 Inhibitor From Enthorin
5